PrecisemAb Biotech participated in the 2025 US BIO International Convention and Bio Asia–Taiwan, showcasing its Universal Antibody Lock technology platform to a global audience. The company has now completed patent coverage in 18 countries and gained significant attention from major pharmaceutical companies across the United States, Europe, and Asia during the exhibitions.
Multiple international partners expressed strong interest in applying the Antibody Lock to ADCs and bispecific antibody development, including opportunities in contract development, technology collaboration, and licensing. These achievements not only highlight PrecisemAb’s growing influence in the global biopharmaceutical landscape but also demonstrate the team’s commitment to advancing innovation in antibody therapeutics.
NEWS: global bio
